Sermorelin Acetate Therapy

Sermorelin differs from growth hormone in that it is a HGH secretagogue, which means that it stimulates the pituitary gland to produce and secrete HGH. Sermorelin is a small peptide containing only 29 amino acids whereas HGH is a much larger molecule containing 191 amino acids

Advertisements for HGH secretagogues that do not require a prescription are not the same as Sermorelin !

If HGH is effective in addressing adult growth hormone deficiency, why should a client consider Sermorelin? For several reasons including the fact that it produces the same effects on body composition and other benefits of HGH but in addition: Its effects are regulated at the level of the pituitary gland by negative feedback and by release of somatostatin so that safety concerns associated the HGH overdosing are minimized or completely avoided; Tissue exposure to HGH released by the pituitary under the influence of Sermorelin is episodic not "square wave" preventing tachphylaxis by mimicking normal physiology; By stimulating the pituitary it preserves more of the growth hormone neuroendocrine axis that is the first to fail during aging; Pituitary recrudescence resulting from Sermorelin blocks the cascade of hypophyseal hormone failure that occurs during aging thereby preserving not only youthful anatomy but also youthful physiology; It provides the patient with all the benefits and more of HGH replacement therapy and furthermore, its OFF LABEL USE IS NOT PROHIBITED BY FEDERAL LAW.

Currently, the only method for effectively administering Sermorelin is by subcutaneous injection. However, because the molecule is much smaller than HGH, it may be possible to successfully administer it through the nasal mucousa using a spray formulation. This hypothesis is currently being tested clinically and the results should soon be known

The dosages of HGH and Sermorelin are fairly similar. Although the molecules work at different sites in the body (HGH at the liver and Sermorelin at the pituitary), the amount of material needed to be effective in raising serum IGF-1 are approximately the same. HGH is generally prescribed in daily doses of one or two international units (IU) while Sermorelin is prescribed in micrograms. However, one IU is equal to 333 micrograms so the weight of effective dosages is approximately between 300 and 600 micrograms per day. The recommended dosages for Sermorelin are between 200 to 500 micrograms per day; a range which is comparable to that for HGH.

Costs of Sermorelin per vial is about 10 - 15% less expensive than HGH. Furthermore, a vial of HGH usually last approximately 12 - 14 days. In contrast, based upon clinical information defining the effective dose for stimulation of the pituitary gland, one multidose vial will be sufficient to last for 15 days.

Loss of HGH potency after about six months or more of continuous use is not unusual and is not due to inferior product. It is due to the fact that injection of HGH elevates blood levels of the hormone to unnaturally high values for several hours each day. Also, constant stimulation causes increased production of IGF-1 which also has more constant tissue exposure than under normal conditions. These factors causes target tissue receptors to "down regulate" in an attempt to prevent over stimulation by the unnatural exposure to HGH and IGF-1. Under physiological conditions, HGH is released from the pituitary gland in episodes that cause levels to increase and decrease many times throughout the day. Under such conditions, tachyphylaxis or down regulation does not occur since the tissues receptors get time to "rest" between each stimulatory event. In contrast to HGH, there is no loss of potency with Sermorelin because its action on the pituitary gland is modulated by feedback through somatostatin. This causes HGH to be released from the pituitary in episodes, rather than in "square wave" pharmacological presentation as occurs upon injection of the gene recombinant product. In addition, the pituitary gland up-regulates to stimulation by Sermorelin causing the gland to rejuvenate are many reports of data in peer-reviewed medical and scientific journals showing that GRF/Sermorelin also has a direct effect on the brain to promote non-REM slow wave sleep.

Sermorelin for injection is available in multidose vials containing sufficient product for 15 days of therapy. Each vial contains from 3 to 7.5 milligrams of Sermorlin as a sterile, lyophilized powder. Sufficient diluent (3 ml sterile, isotonic saline) is provided so that each 0.2 milliliter of the reconstituted solution contains daily doses ranging from 200 to 500 micrograms Sermorelin .